NEW YORK (GenomeWeb) – Invivoscribe announced today that it has received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA)for its LeukoStrat CDx FLT3 Mutation Assay companion diagnostic.

The firm expects to begin shipments of the FTL3 assay from LabPMM GK, the assay's marketing authorization holder in Japan, in late 2018.